TrialNature medicine2022

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.

Solange Peters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.